GlassScriptPhysician profile
Theodore Bross
NPI 1750886131
$1,624.31
in general payments reported to CMS, 2019-2025
23 companies · $457 in 2025
The $457 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.08 · 2022: $656 · 2023: $13.76 · 2024: $472 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.97 | 2022-2025 | Ubrelvy |
| Lilly USA, LLC | $135.35 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $120.88 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.68 | 2022-2024 | Breztri |
| Bausch Health US, LLC | $90.01 | 2024-2025 | Aplenzin |
| Glaxosmithkline, LLC. | $80.33 | 2021-2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $78.42 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $69.96 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $68.00 | 2025 | Veozah |
| Novo Nordisk INC | $63.06 | 2022 | |
| Amgen INC. | $61.46 | 2022-2025 | Repatha, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $49.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $42.67 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Kowa Pharmaceuticals America, INC. | $36.88 | 2022 | |
| Boston Scientific Corporation | $32.25 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.26 | 2024 | |
| Exact Sciences Corporation | $28.79 | 2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $27.41 | 2022 | |
| Merck Sharp & Dohme LLC | $21.90 | 2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Exeltis, USA INC. | $16.17 | 2024 | Slynd |
| Idorsia Pharmaceuticals US INC | $15.67 | 2022 | |
| Grifols USA, LLC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Bross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.